206446-39-1

Basic information

• Product Name: tert-butyl 3-(pyridin-2-yl)azetidine-1-carboxylate
• Synonyms: tert-butyl 3-(pyridin-2-yl)azetidine-1-carboxylate;3-Pyridin-2-yl-azetidine-1-carboxylic acid tert-butyl ester
• CAS NO: 206446-39-1
• Molecular Formula: C13H18N2O2
• Molecular Weight: 234.3
• Mol File: 206446-39-1.mol

Chemical Properties

• Boiling Point: 343.9±35.0 °C(Predicted)
• Appearance: /
• Density: 1.133±0.06 g/cm3(Predicted)
• PKA: 5.18±0.19(Predicted)
• CAS DataBase Reference: tert-butyl 3-(pyridin-2-yl)azetidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 3-(pyridin-2-yl)azetidine-1-carboxylate(206446-39-1)
• EPA Substance Registry System: tert-butyl 3-(pyridin-2-yl)azetidine-1-carboxylate(206446-39-1)

Safety Data

• Hazardous Substances Data: 206446-39-1(Hazardous Substances Data)

Upstream product

• 109-04-6 2-bromo-pyridine 
• 206446-38-0 (1-(tert-butoxycarbonyl)azetidin-3-yl)zinc(II) iodide 
• 254454-54-1 tert-butyl-3-iodoazetidine-1-carboxylate 
• 110-86-1 pyridine 
• 141699-58-3 3-methanesulfonyloxy-azetidine-1-carboxylic acid tert-butyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 206446-45-9 2-(azetidin-3-yl)pyridine dihydrochloride 

Relevant articles and documents

Synthetic method of antitumor heterocyclic drug intermediate 2-(3-azacyclobutyl) pyridine dihydrochloride

The invention discloses a synthetic method of an antitumor heterocyclic drug intermediate 2-(3-azacyclobutyl) pyridine dihydrochloride. The synthetic method specifically comprises the following step of performing a two-step reaction to obtain a target compound 2-(3-azacyclobutyl) pyridine dihydrochloride by taking 3-iodine-1-t-butyloxycarboryl azetidine and 2-bromopyridine as raw materials. According to the synthetic method disclosed by the invention, the used raw materials are simple, low in cost and easily available, the reaction condition is simple, and the obtained product is high in chemical purity.

Continuous synthesis of organozinc halides coupled to Negishi reactions

The Negishi cross-coupling is a powerful C-C bond forming reaction. The method is less commonly used relative to other cross-coupling methods in part due to lack of availability of organozinc species. While organozinc species can be prepared, problems wit

Discovery of azetidine based ene-amides as potent bacterial enoyl ACP reductase (FabI) inhibitors

A novel and potent series of ene-amides featuring azetidines has been developed as FabI inhibitors active against drug resistant Gram-positive pathogens particularly staphylococcal organisms. Most of the compounds from the series possessed excellent biochemical inhibition of Staphylococcus aureus FabI enzyme and whole cell activity against clinically relevant MRSA, MSSA and MRSE organisms which are responsible for significant morbidity and mortality in community as well as hospital settings. The binding mode of one of the leads, AEA16, in Escherichia coli FabI enzyme was determined unambiguously using X-ray crystallography. The lead compounds displayed good metabolic stability in mice liver microsomes and pharmacokinetic profile in mice. The in vivo efficacy of lead AEA16 has been demonstrated in a lethal murine systemic infection model.

AMINO-HETEROCYCLIC COMPOUNDS

The invention provides PDE9-inhibiting compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, A, and n are as defined herein. Pharmaceutical compositions containing the compounds of Formula I, and uses thereof in treating neurodegenerative and cognitive disorders, such as Alzheimer's disease and schizophrenia, are also provided.

Synthesis of C-substituted cyclic amines using azacycloalkyl organozinc reagents

Azetidine and piperidine derived organozinc species have been prepared from the corresponding azacycloalkyl iodides by direct Zn insertion. They have been shown to readily undergo Pd(0) mediated cross-coupling reactions and to transmetallate with CuCN.2LiCl.